Background: FOLFIRINOX (FFX) and gemcitabine (GEM) plus nab-paclitaxel (GnP) have recently been available for treating pancreatic ductal adenocarcinoma (PDAC). We investigated trends in characteristics, treatment and outcomes of unselected patients with unresectable PDAC in real-life practice in Japan. Methods: We retrospectively reviewed the medical records of 1085 patients diagnosed as having unresectable or recurrent PDAC in multiple centers in the Hokuriku area between January 2009 and July 2015.
Introduction
Pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive malignancies, has a 5-year survival rate of <5% (1). Its incidence is continuing to increase and it is now the third leading cause of cancer death worldwide (2) because so few patients are candidates for surgical resection, which is currently the only potentially curative therapy despite recent advances in diagnostic techniques (3) . Three effective protocols have been available for patients in Japan with unresectable or recurrent PDAC in the last seven years; namely gemcitabine (GEM) plus erlotinib (GE) since July 2011, folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX, FFX) since December 2012, and gemcitabine plus nab-paclitaxel (GnP) since December 2013. This availability was based on the results of several randomized controlled trials that showed significant improvement in overall survival (OS) compared with gemcitabine monotherapy (4) (5) (6) . Consequently, the treatment recommended by the National Comprehensive Cancer Network clinical guidelines has changed during this period (7) .
However, conditions in clinical practice differ from those in clinical trials as some patients with PDAC have contraindications to administration of the optimal therapy as shown in clinical trials. Moreover, even for patients who are fit enough to tolerate such treatment, treatment selection depends on the patients' and physicians' decisions, which, although greatly influenced by results of clinical trials, are also influenced by the efficacy and safety of such treatment in the real-world (8) . A few studies have previously reported characteristics and outcomes of patients with PDAC based on data from registries (9-11); however, those studies did not provide detailed information about unselected patients with PDAC who had been treated with recently approved chemotherapeutic agents.
Thus, we investigated the characteristics, treatment patterns, outcomes and changes with time of patients with unresectable, and recurrent PDAC in real-life practice in Japan.
Methods

Objective patients
Data on consecutive patients who had been diagnosed as having PDAC at the Kanazawa University Hospital and 21 of its affiliated hospitals between January 2009 and July 2015 were retrospectively studied. The 22 hospitals were of various size and located in the Hokuriku area of Japan, which consists of Toyama, Ishikawa and Fukui prefectures, and including private, public and a university hospital. This study included all patients judged to be unsuitable to undergo surgical resection by each doctor in charge, mainly on the basis of radiological findings of major artery and/or portal vein invasion, detection of metastases, or recurrence after surgical resection. All patients were diagnosed as having PDAC on the basis of radiological and/or pathological findings. Patients with non-adenocarcinoma histology, such as neuroendocrine tumor, acinar cell carcinoma or aplastic cell carcinoma, were excluded, as were patients whose tumors were considered resectable or borderline resectable.
Data collection
Eligible patients' medical records and collected clinicopathological data were reviewed. These included age, sex, Eastern Cooperative Oncology Group performance status (ECOG PS), laboratory data, tumor markers, pathological diagnosis, imaging data, clinical stage according to the UICC TNM classification, response to treatment according to the Response Evaluation Criteria in Solid Tumors version 1.1, adverse events according to the Common Terminology Criteria for Adverse Events version 4.0, and outcomes. Case report forms were collected from the 22 participating hospitals twice; the first data collection cut-off was 30 September 2012 for patients diagnosed between January 2009 and July 2012, and the second 31 December 2015 for patients diagnosed between August 2012 and July 2015. We did not update the data about the patients diagnosed between January 2009 and July 2012 at the time of second data collection cut-off. The Institutional Review Boards of Kanazawa University Hospital and of all participating institutions approved the study protocol, and the study was conducted in accordance with the Declaration of Helsinki.
Statistical analysis
Patient characteristics were compared between groups using the χ 2 -test for categorical variables in univariate analysis, and logistic regression analysis in multivariate analysis. Cut-off levels of continuous variables were set as the median in the relevant group. The χ 2 -test and logistic regression analysis were also used to evaluate relationships between groups and responses to treatment. OS was calculated from the date of diagnosis to the date of death or the last day of the follow-up period. Treatment duration was calculated from the first to the last day of treatment. To compare OS and treatment duration between groups, cumulative survival was calculated using the Kaplan-Meier method and differences between groups evaluated using Cox's proportional hazards regression model. Only variables that achieved statistical significance in the univariate analysis were subsequently evaluated by multivariate analysis using Cox's proportional hazards regression model. A P-value of less than 0.05 was considered to denote statistical significance. Data analyses were performed using Stata 12.1 (College Station, TX, USA). Table 1 . The median age was 73 years, and 53.5% were men; 27.1% had locally advanced and 67.4% metastatic disease, and 6% had recurrences. Anticancer therapy had been administered to 779 patients (71.8%), including chemotherapy, chemo-radiotherapy and radiotherapy, whereas 306 patients (28.2%) had received only best supportive care (BSC) (Fig. 1) . Older age, worse ECOG PS and ascites occurred more often in BSC group (Table 1) . Overall, 41.2% of the patients had pathologically proven adenocarcinomas. The proportion of patients with pathological diagnoses had increased over the year of the study and had been obtained more frequently in the anticancer therapy group than the BSC group (55.9% vs. 18.0%; P < 0.001) ( Table 2 ).
Results
Characteristics of patients
Patient outcomes according to clinical characteristics
The median duration of follow-up was 5.6 months (0.03-42.4) and 833 patients (76.8%) had died by the day of data collection cut-off. The median OS of all patients was 6.8 months, and the 6-month, 1-year and 2-year survival rates were 54.3%, 28.2% and 10.4%, respectively (Supplementary Figure 1) . The median OS of the patients in anticancer therapy and BSC groups were 9.0 months and 2.0 months, respectively (Supplementary Figure 2) .
The following nine of the 16 pretreatment variables that were evaluated were identified as being significantly associated with OS among all patients (Table 3) : age ≥73 years, ECOG PS 2-4, metastatic disease compared with locally advanced disease, ascites, CRP concentration ≥0.7 mg/dL, ALP ≥359 IU/L, LDH ≥212 IU/L, CEA ≥6.3 ng/mL and CA19-9 U/mL ≥702.5. The same nine of the 16 pretreatment variables were also identified as being significantly associated with OS in the anticancer therapy group (Supplementary Table 1) : age ≥70 years, ECOG PS 2-4, UICC metastatic disease compared with locally advanced disease, ascites, CRP ≥0.4 mg/dL, ALP ≥324 IU/L, LDH ≥202 IU/L, CEA ≥5.4 ng/mL and CA19-9 ≥552.9 U/mL. In contrast, the following four of the 16 pretreatment variables were identified as being significantly associated with OS in the BSC group (Supplementary Table 2) : ascites, WBC ≥7 400 /mm 3 , CRP ≥1.9 mg/dL and CEA ≥9.6 ng/mL.
Initial treatment
During the study period, the initial therapy was chemotherapy in 675 patients (62.2%), chemo-radiotherapy in 92 (8.5%) and radiotherapy in the remaining 12 (1.1%) (Fig. 1) .
GEM monotherapy was the most commonly used first-line chemotherapy protocol (365 patients), followed by a combination of GEM and S-1 (GS) in 106 patients, S-1 monotherapy in 99, FFX in 47, GE in 26, GnP in 20 and other protocols in the remaining 12 patients. The first-line chemotherapeutic protocol changed markedly during the study period, as shown in Fig. 2 . In 2009, 62.0% of treated patients received monotherapy with GEM as first-line chemotherapy, this proportion gradually decreasing to 22.7% in 2015. Alternative selection of S-1 monotherapy increased to about 20% after 2012, conversely FFX or GnP were administered to 30.7% and 25.3% of patients, respectively, in 2015.
In the 92 patients receiving chemo-radiotherapy as initial therapy, GEM was combined with radiotherapy in 64 patients and with 5-FU or S-1 in 28 patients. GEM was most frequently used between 2009 and 2011, after which the proportion of patients receiving 5-FU or S-1 gradually increased.
Of the 294 patients with locally advanced disease, 55 received BSC and 239 any anticancer therapy, including 155 (67.7%) who received chemotherapy, 75 (32.8%) who received chemo-radiotherapy, and nine (3.9%) who received radiotherapy as initial therapy. This distribution did not change during the study period (Supplementary Figure 3) .
Patient characteristics according to initial treatment are summarized in Supplementary Table 3 . UICC Stage IV, recurrence and high CRP concentration were significantly more frequently observed in patients receiving chemotherapy than in those receiving chemo-radiotherapy.
Response to chemotherapy and patient outcomes according to initial treatment
Information about response to treatment was available for 575 of the 675 patients (85.2%). Three (0.4%), 64 (9.5%) and 272 patients (40.3%) achieved complete response, partial response and stable disease, respectively; thus, the objective response rate to chemotherapy was 9.9%. These results varied greatly according to the chemotherapeutic protocol. The objective response rates to GEM, S-1, GS, GE, FFX and GnP were 5.5, 11.1, 17.0, 7.7, 14.9 and 35.0%, respectively, and GS, FFX and GnP were significantly better than to GEM (Supplementary Table 4 ). The cut-off levels for continuous variables were set as the median value in that patient group. Table 4 ). There were similar tendencies among patients with ECOG PS 0 or 1 and aged 75 years or younger. Compared with patients receiving GEM, those receiving S-1 and FFX had significantly longer survivals (HR 0.676 and 0.615, respectively), whereas those receiving GS and GnP had a non-significant tendency to have longer survivals (HR 0.765 and 0.468, respectively) (Supplementary Table 5 ). Similar differences in efficacy were not detected among patients with ECOG PS 2 or worse and/or aged over 75 years (Supplementary Table 6 ).
Median OS were 14.3 and 12.9 months in patients with locally advanced disease who received chemo-radiotherapy and chemotherapy, respectively. Median OS did not differ between groups for chemotherapy with a single agent (GEM or S-1 monotherapy) or the combinations of GS, GE, GnP or FFX (Supplementary Table 7) .
Adverse events and tolerability of chemotherapy
All 675 patients were assessed for adverse events; toxicity profiles of chemotherapy are summarized in Table 4 . Hematological toxicities were common, particularly Grade 3/4 neutropenia, anemia and thrombocytopenia, which occurred in 174 (25.8%), 73 (10.8%) and 50 patients (7.4%), respectively. The frequency of all hematological toxicities and some non-hematological toxicity had a tendency to be higher in patients receiving a combination protocol than in those receiving GEM.
Of the 615 patients whose treatment was terminated, the reason for termination was tumor progression in 424 patients (68.9%), adverse events in 164 patients (26.7%), and other reasons in the remaining 27 (4.4%). The proportion of the patients whose treatment was terminated because of adverse events was similar for most chemotherapy protocols, an exception being that it was significantly higher in patients treated with GS (37.1%) than in those receiving GEM (24.1%) and FFX (9.8%) (Supplementary Table 8 ).
Treatment duration differed between chemotherapy protocols. Patients receiving GEM, S-1, GS, GE, FFX or GnP had median treatment durations of 2.8, 2.9, 3.5, 2.8, 3.0 and 3.6 months, respectively. Compared with patients receiving GEM, those receiving GS had a significantly longer treatment duration (HR 0.685), whereas those receiving FFX and GnP had a tendency to have a longer treatment duration (HR 0.768 and 0.749, respectively) (Supplementary Table 4 ).
Discussion
In this study, we collected and assessed information about clinical characteristics, treatment patterns and outcomes of a large number of patients with unresectable PDAC. We collected case report forms from institutions of various size and characteristics, including small private clinics, public community hospitals and a university hospital. Our study cohort comprised about one-third of all estimated patients in the study area according to population-based cancer registry data (12) . Here, follow our most interesting findings about clinical characteristics, treatment patterns and outcomes of patients with unresectable PDAC.
First, our findings are based on data on patients in real-life practice and were not obtained from clinical trials or existing registries. For example, in our cohort, 28.4% of patients received BSC and this percentage did not change during the study period. Previous have found that about half of patients with PDAC do not receive any anticancer therapy (13, 14) . One possible explanation for the lower percentage of such patients in this study is that there is universal health coverage in Japan, which leads to easier access to anticancer drugs (15) . However, this easier access may be problematic regarding adverse events and costs of overtreatment with GEM and new combination protocols (16, 17) . Another important finding is that prognostic factors differed between the BSC and treatment groups, which may help patients and their families to predict outcomes and thus make more informed decisions about whether to accept anticancer therapy.
Next, in our study the diagnosis was verified by pathological examination in only 41.2% of patients, which is a lower proportion than we expected or has been previously reported (13, 14) . This proportion may depend on patients' demand for a definitive diagnosis, the date of the survey, facilities available in the institution, or the intention to administer anticancer therapy. The proportion with pathologically-confirmed diagnoses has rapidly increased to 73.3% for patients in the anticancer therapy group diagnosed in the last 7 years, this increase probably being attributable to the introduction of endoscopic ultrasonography-guided fine-needle aspiration and increasing recognition of other histological types of pancreatic cancer, such as neuroendocrine tumors, associated with development of new drugs. Because a definitive diagnosis is recommended for patients who intend to receive chemotherapy, we expect that this proportion will continue to increase. In contrast, it seems reasonable that this proportion remains low in the BSC group in view of these patients' symptoms and the risk of endoscopic examination.
GEM was the main first-line chemotherapy for patients with unresectable PDAC after it was approved for health coverage in Japan in 2001. The following pronounced changes in chemotherapy protocols used in real-life practice are the most striking findings of this study: (1) use of S-1 increased and use of GS decreased after the results of the GEST study were reported in 2011 (18); (2) only a few patients received GE and (3) about 40% of the study patients still received GEM or S-1 after GnP and FFX became available. The last point indicates that the best protocol for patients who are ineligible for clinical trials remains under discussion because they tend to be older, in worse general condition, and to have impairment of major organ functions. Combination protocols were not effective in patients with ECOG PS 2 or worse and/or aged over 75 years, as shown in Supplementary Table 5 .
On the other hand, our findings suggested that FFX and GnP seemed well-tolerable despite frequent adverse events in patients suitable for them in also real-life practice. Especially, the proportion of the patients discontinuing FOLFIRINOX because of adverse events seemed to be lower than that of the patients with gemcitabine, S-1, or gemcitabine plus S-1 in this study as well as that of the patients in Phase II study in Japan (19.4%) (19) . A possible reason for well-tolerability for FOLFIRINOX included careful selection of the eligibility based on the finding that 41 of the 47 patients treated by FOLFIRINOX has ECOG PS 0 or 1 and aged ≤70 in this study (data not shown). Another consideration was that the development of modified protocols of FOLFIRINOX with better tolerability (20) . In contrast, 14.9% of the objective response rate and 3.0 months of the median treatment duration suggested that the efficacy of FOLFIRINOX in this study may be not as good as that of clinical trial (19) . In general, a chemotherapeutic treatment in real-life practice has tendency to show worse efficacies than that in clinical trial, and recent retrospective observation studies from Japan described that the objective response rate to FOLFIRINOX was 6.3-21%, and progression-free survival time was 3.7-4.5 months (21, 22) . We considered that our results were comparable to those of these reports considering the difference of progression-free survival time and the treatment duration calculated from the first to the last day of treatment in this study. In both cases, very limited patients Table 4 . Adverse events during chemotherapy according to chemotherapeutic protocol receiving new combination protocols and short observation period for those patients in this study did not allow us to reach any definite conclusion. Thus, further investigation of larger numbers of patients is needed. The present study has several limitations. For instance, not all patients included in this study had pathologically proven adenocarcinoma although non-adenocarcinoma histology was minority of the patients with pancreatic cancer and patients with such histology were excluded in this study. Next, participating hospitals to this region-wide analysis was restricted to be located in Hokuriku area that is comparatively rural area in Japan. We believed that medical care in this area was comparable to that of other area owing to promotion of the Basic Plan to Promote Cancer Control Programs and universal health coverage in Japan. However, the results of this study may not reflect those of entirely Japan because of the possible existence of regional difference such as distribution of patient's age or selected treatment pattern. Other limitations included its retrospective and non-randomized design, unbalanced patient's characteristics between groups, the heterogeneous treatment protocols and short duration of follow-up.
We therefore plan to continue to review these data because reallife practice is not static, and a further well-designed prospective study with longer follow-up will provide more definitive findings.
Conclusions
In conclusion, we have here presented data on a region-wide multicenter cohort of patients with unresectable PDAC in real-life practice, including their characteristics, treatment patterns and outcomes. We identified pronounced changes in chemotherapy treatment of these patients over the years of the study. Continuous collection of these data from a region-wide cohort with longer follow-up provides useful information about treatment selection and prediction of outcome.
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Supplementary data are available at Japanese Journal of Clinical Oncology online.
